What Makes an Effective PROTAC? Unlocking Drug-Resistant Pathways Through Warhead, Linker, and Anchor Modifications

By: Ell Siti Macpherson Abstract

PROTACs (PROteolysis TArgeting Chimeras) are a novel class of therapeutic molecules that induce the degradation of target proteins by hijacking the ubiquitin-proteasome system. This study focuses on the theoretical design of PROTAC candidates targeting CDK9, a key kinase involved in transcriptional regulation and a validated cancer target. Five PROTAC prototypes were developed by combining distinct warheads (e.g., Wogonin, AT7519), linker motifs (PEG, triazole, alkyl, amide), and E3 ligase-recruiting anchors (VH032, VH298, thalidomide derivatives). Each design was justified based on predicted degradation efficiency, solubility, flexibility, and selectivity. Although not yet experimentally validated, the candidates are expected to exhibit favorable pharmacological properties and effective CDK9 degradation. Proposed next steps include in vitro cell viability assays, Western blot analysis, and eventual in vivo evaluation to assess therapeutic potential. These designs lay the groundwork for future studies in targeted protein degradation for cancer therapy.

Introduction

PROTACs or Proteolysis targeting chimeras are molecules that contain three parts. The E3 ligase recognition moiety, the linker, and the ligand for target protein. Protacs were first reported by Sakamoto et al back in 2001.1 Protacs represents a transformative approach in modern drug discovery. Unlike traditional small-molecule inhibitors, which block the active site of proteins, PROTACs hijack the cell’s natural ubiquitin proteasome system to degrade disease-causing proteins entirely. This makes PROTACs particularly valuable for addressing “undruggable” targets, proteins without suitable binding pockets for conventional drugs. To sum that up: A PROTAC (short for PROteolysis TArgeting Chimera) is a special type of medicine that helps the body get rid of harmful proteins. Unlike traditional small molecule drugs that often fail to bind or affect certain disease related proteins, PROTACs act like highly specialized ‘smart drugs’ engineered to hijack the cell’s own degradation system to eliminate previously ‘undruggable’ targets.

One such promising target is cyclin-dependent kinase-9 (CDK9), a key regulator of transcriptional elongation and a validated target in various cancers (leukemia, solid tumors, etc). PROTAC mediated degradation offers a strategy by removing CDK9 from the cell entirely, potentially increasing specificity while reducing off-target effects.2

In this research project, I designed a series of theoretical PROTAC candidates targeting CDK9. Each candidate consists of a Warhead (e.g., Wogonin, AT7519),3 a Linker motif (e.g., Triazole, Alkyl, or Amide chains), and a ligase recruiting Anchor (e.g., VH-032, Thalidomide, Lenalidomide).

By varying linker length and flexibility, especially through adjustments in alkyl chain length. I aimed to evaluate how these modifications might affect degradation efficiency, membrane permeability, and ternary complex formation. Although these candidates have not been tested experimentally, this paper outlines the rationale behind their design and proposes next steps for future in vitro and in vivo validation.4

To develop effective PROTACs targeting CDK9, I designed a set of candidate moleculescomposed of three main components: a Warhead, a Linker motif, and an Anchor. Each elementwas chosen based on existing research, drug likeness, and potential for stable ternary complexformation.

Theoretical Evaluation

Using literature based insights and visual modeling of molecular distances, I analyzed which linker combinations might best position the warhead and anchor for successful protein and ligase interaction. Candidates with longer alkyl chains were expected to give more flexibility but less specificity, while shorter/ rigid linkers might enhance selectivity but risk poor binding orientation.6

Literature Review

PROTACs (PROteolysis TArgeting Chimeras) are a new type of drug that break down harmful proteins in cells by using the cell’s natural recycling system called the ubiquitin-proteasome pathway. Instead of just blocking a protein’s function like traditional drugs, PROTACs help remove the protein completely. A typical PROTAC is made of three parts: a warhead that binds to the target protein, a linker that connects the parts, and an anchor that recruits an E3 ligase enzyme to mark the protein for destruction.

Recent studies have shown that changing each of these parts can affect how well the PROTAC works. For example, using known CDK9 inhibitors like Wogonin or AT7519 as warheads increases target binding. PEG and triazole linkers are often used to improve solubility and allow flexibility, which helps the PROTAC form a stable complex with both CDK9 and the ligase. Anchors like VH032 and thalidomide derivatives guide the PROTAC to different E3 ligases such as VHL or CRBN, influencing how the protein is tagged and removed. Overall, these design choices play a key role in making PROTACs effective tools for targeted cancer therapy7, especially for hard-to-drug targets like CDK9.

Methodology

This study focuses on the theoretical design of five PROTAC molecules aimed at degrading CDK9, a key kinase involved in cancer-related transcription. Each PROTAC was composed of three essential components: a warhead, a linker, and an anchor, more specifically a E3 ligase-recruiting anchor.The warheads, Wogonin and AT7519, were selected based on their reported ability to bind and inhibit CDK9. These molecules have shown anti-cancer activity in previous studies, making them suitable starting points for targeted protein degradation.8

To study the effects of linker flexibility and solubility, various linkers (PEG chains, triazoles, alkyl chains, and amides) were used. Their length and polarity were varied to assess impact on ternary complex stability between the PROTAC, CDK9, and the E3 ligase. VH032, VH298, and thalidomide based ligands were used to recruit VHL or CRBN, enabling the comparison of degradation efficiency across ligase systems.9

All five PROTAC candidates were designed manually using chemical logic and findings from previous research. While no laboratory testing has been done, these designs aim to provide a strong foundation for future synthesis and biological evaluation.10

Proposed Results & Discussion

Since these PROTAC candidates have not yet been tested experimentally, their structural design suggests several potential advantages based on known scientific principles and earlier studies.

All candidates are expected to form stable ternary complexes involving CDK9, the E3 ligase, and the PROTAC itself. Those using VH032 or VH298 are predicted to bind strongly to the VHL ligase11, which may result in efficient tagging and degradation of CDK9 through the proteasome system. In contrast, PROTACs with thalidomide based anchors are designed to recruit the CRBN ligase, offering an alternative degradation route and helping compare ligase selectivity and efficiency.

Linker composition and length play a vital role in PROTAC performance. PEG and triazole linkers are likely to enhance solubility and flexibility, improving the molecule’s ability to bring the target protein and ligase into close proximity. For example, Candidate 3, which uses a shorter alkyl linker, may offer greater specificity with fewer off-target effects. Meanwhile, Candidate 5, designed with a longer, flexible linker, may achieve better degradation due to enhanced reach and adaptability.

From a drug development perspective, candidates featuring PEG or triazole linkers may also show improved cell permeability and solubility, which are important traits for effective therapies. The warheads, Wogonin and AT7519, contribute additional therapeutic value because of their known CDK9 inhibiting and anti cancer properties.

Overall, the proposed PROTACs appear promising for selective CDK9 degradation. However, experimental testing is essential to confirm their effectiveness, selectivity, and drug-like behavior. These designs provide a strong starting point for future research and development in targeted protein degradation strategies.

Future Work

To advance the designed PROTAC candidates toward therapeutic relevance, several experimental steps are required:

1. Cell Viability Assays

Test the anti-cancer effects of each PROTAC candidate by measuring their ability to reduce viability in CDK9 dependent cancer cell lines.

2. Western Blotting for Degradation Confirmation

Use Western blot analysis to verify that CDK9 levels decrease after PROTAC treatment, confirming effective protein degradation.

3. Stability and Solubility Testing

Assess the chemical and metabolic stability of each compound, as well as solubility in physiological conditions, to evaluate drug-like properties.

4. Selectivity Profiling

Perform proteomic screening to identify potential off-target effects and ensure that degradation is specific to CDK9.

5. In Vivo Evaluation

Advance the most promising candidates into animal studies to assess

pharmacokinetics, biodistribution, and therapeutic efficacy in tumor models.

6. Optimization of Linkers and Delivery

Refine linker structure to improve degradation efficiency and explore delivery systems (e.g nanoparticles or prodrugs) to enhance bioavailability.

7. Resistance and Long-Term Response Studies

Investigate whether cells develop resistance to degradation over time and assess how long-term PROTAC exposure affects cellular signaling pathways.

These steps will provide a comprehensive understanding of the therapeutic potential, safety, and limitations of each designed candidate.

Conclusion

This study presents a theoretical framework for designing novel PROTAC candidates targeting CDK9, a key regulator of cancer-related transcription. By exploring variations in warheads, linker motifs, and E3 ligase-recruiting anchors, I developed five structurally diverse compounds with predicted advantages in degradation efficiency, solubility, and selectivity. While experimental validation is still required, the proposed candidates provide a promising foundation for future in vitro and in vivo testing, with the ultimate goal of developing effective and selective therapeutics for cancer treatment.

References

1. Troup, R. I., Fallan, C., & Baud, M. G. J. (2020). Current strategies for the design of PROTAC linkers: A critical review. Exploration of Targeted Anti-tumor Therapy, 1, 273–312. https://doi.org/10.37349/etat.2020.00018

2. Ayinde, O. R., Sharpe, C., Stahl, E., Tokarski, R. J., Lerma, J. R., Muthusamy, N., Byrd, J. C., & Fuchs, J. R. (2023). Examination of the impact of triazole position within linkers on solubility and lipophilicity of a CDK9 degrader series. ACS Medicinal Chemistry Letters, 14(7), 936–942. https://doi.org/10.1021/acsmedchemlett.3c00012

3. Gong, H., Zeng, H., Li, J., Yang, S., & Zhou, D. (2022). Targeted protein degradation strategies for cancer therapy: Advances and challenges. Acta Pharmaceutica Sinica B, 12(11), 4727–4748. https://doi.org/10.1016/j.apsb.2022.04.010

4. Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., ... & Crews, C. M. (2015). Catalytic in vivo protein knockdown by small-molecule PROTACs. Nature Chemical Biology, 11(8), 611–617. https://doi.org/10.1038/nchembio.1858

5. Burslem, G. M., & Crews, C. M. (2020). Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell, 181(1), 102–114.

https://doi.org/10.1016/j.cell.2020.01.034

6. Churcher, I. (2018). Protac-induced protein degradation in drug discovery: Breaking the rules or just making new ones? Journal of Medicinal Chemistry, 61(2), 444–452. https://doi.org/10.1021/acs.jmedchem.7b01263

7. Cicenas, J., & Cicenas, E. (2016). Multi-kinase inhibitors in cancer treatment: Past, present and future. Cancer Chemotherapy and Pharmacology, 77(6), 1103–1114. https://doi.org/10.1007/s00280-016-3036-z

8. Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., ... & Ciulli, A. (2017). Structural basis of PROTAC cooperative recognition for selective protein degradation. Nature Chemical Biology, 13(5), 514–521.

https://doi.org/10.1038/nchembio.2329

9. Testa, A., Hughes, S. J., Lucas, X., Wright, J. E., Ciulli, A., & Wilson, D. M. (2020). Structure-based design of PROTACs: An overview of binding cooperativity and linker strategies. Future Medicinal Chemistry, 12(2), 135–163.

https://doi.org/10.4155/fmc-2019-0184

10. Pettersson, M., & Crews, C. M. (2019). PROteolysis TArgeting Chimeras (PROTACs)—Past, present and future. Drug Discovery Today: Technologies, 31, 15–27. https://doi.org/10.1016/j.ddtec.2019.01.002

11. Zengerle, M., Chan, K.-H., & Ciulli, A. (2015). Selective small molecule induceddegradation of the BET bromodomain protein BRD4. ACS Chemical Biology, 10(8),1770–1777. https://doi.org/10.1021/acschembio.5b00216